Importance There is currently no consensus as to which biomarkers best predict longitudinal
tau accumulation at different clinical stages of Alzheimer disease (AD). Objective To
describe longitudinal [18 F] RO948 tau positron emission tomography (PET) findings across
the clinical continuum of AD and determine which biomarker combinations showed the
strongest associations with longitudinal tau PET and best optimized clinical trial enrichment.
Design, Setting, and Participants This longitudinal cohort study consecutively enrolled …